Nuvalent (NUVL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO, with all board members and key executives introduced.
Meeting held virtually, following the format from the previous year.
Rules of conduct and participation outlined for attendees.
Corporate governance
Notice of meeting and proxy statement were sent to all stockholders of record as of April 20, 2026.
Quorum established with a majority of Class A common stock represented.
Board and executive committee updates
Election of two Class 2 directors for a three-year term was on the agenda.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Nuvalent
- Two major drug launches in 2024, with neladalkib poised to shift ALK treatment standards.NUVL
Jefferies Global Healthcare Conference 20264 Jun 2026 - Two commercial launches and pivotal trial progress position the pipeline for major impact in oncology.NUVL
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA27 May 2026 - Pivotal data for lead NSCLC therapies support 2026 launches and strong market growth.NUVL
Corporate presentation27 May 2026 - Q1 2026 net loss was $109.3M as lead oncology programs reached NDA stage and cash stood at $1.3B.NUVL
Q1 20267 May 2026 - Director elections, executive pay, and auditor ratification up for vote at June 2026 meeting.NUVL
Proxy filing28 Apr 2026 - Proxy covers director elections, executive pay, auditor ratification, and governance highlights.NUVL
Proxy filing28 Apr 2026 - Pivotal NSCLC data and FDA filings set stage for commercial launches and global expansion.NUVL
44th Annual J.P. Morgan Healthcare Conference14 Apr 2026 - Pivotal data and regulatory progress position the pipeline for major NSCLC market impact.NUVL
Corporate presentation13 Apr 2026 - Strong clinical data and rapid enrollment position ROS1 and ALK drugs for global launch.NUVL
Leerink Global Healthcare Conference 20269 Mar 2026